Business Context and Reporting Period
Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 10-Q
Reporting Period: Three months ended March 31, 2025
Business Overview: Corcept is a commercial-stage biopharmaceutical company focused on treating severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol. Its primary commercial products are Korlym and an authorized generic version, used to treat hyperglycemia secondary to hypercortisolism (Cushing's syndrome). The company is also advancing a pipeline of selective cortisol modulators, including relacorilant (hypercortisolism and oncology), dazucorilant (ALS), and miricorilant (MASH).
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Product Revenue, Net | $157,214 | $146,808 |
| Cost of Sales | $2,403 | $2,535 |
| Gross Margin | 98.5% | 98.3% |
| Operating Expenses | $153,798 | $117,308 |
| Income from Operations | $3,416 | $29,500 |
| Net Income | $20,547 | $27,762 |
| Diluted EPS | $0.17 | $0.25 |
| Cash and Cash Equivalents | $89,819 | $149,750 (End of Period) |
| Total Cash, Equivalents & Marketable Securities | $570,800 | $603,200 (Dec 31, 2024) |
| Net Cash Provided by Operating Activities | $5,128 | $23,756 |
Liquidity: As of March 31, 2025, the company held $570.8 million in cash, cash equivalents, and marketable securities. The company expects to fund operations for the next 12 months without raising additional capital.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 7.1% to $157.2 million, driven by a 23.5% increase in sales volume. This was partially offset by a 13.3% decrease in average price due to higher sales of the authorized generic version of Korlym.
- Operating Expenses: Total operating expenses rose 31.1% to $153.8 million.
- R&D: Increased 3.8% to $60.7 million, primarily due to higher employee compensation and advancement of development programs (specifically Hypercortisolism and Metabolic diseases), offset by lower Oncology spend as programs near completion.
- SG&A: Increased significantly by 61.1% to $90.7 million, driven by increased employee compensation and expanded sales and marketing activities.
- Profitability: Income from operations declined 88.4% to $3.4 million due to the sharp rise in operating expenses. Net income decreased 26.0% to $20.5 million, aided by an income tax benefit of $10.9 million (compared to an expense of $7.2 million in Q1 2024).
- Cash Flow: Net cash provided by operating activities decreased 78.4% to $5.1 million, primarily due to lower net income and changes in working capital (specifically increases in prepaid expenses and decreases in accrued liabilities).
- Capital Allocation: The company repurchased 0.5 million shares for $27.4 million under its stock repurchase program. Total cash used in financing activities was $39.8 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Relacorilant (Hypercortisolism): The FDA accepted the New Drug Application (NDA) in March 2025 with a Prescription Drug User Fee Act target action date of December 30, 2025. The application is supported by positive results from the GRACE and GRADIENT Phase 3 trials.
- Relacorilant (Oncology): The Phase 3 ROSELLA trial in platinum-resistant ovarian cancer met its primary endpoint for Progression-Free Survival (PFS) and showed positive interim Overall Survival (OS) results. A Phase 2 trial (BELLA) was initiated in April 2025.
- Commercial Strategy: The company continues to invest in sales and marketing to support Korlym and the authorized generic, while managing the impact of generic competition from Teva and potential future entrants (Sun, Hikma).
- Regulatory Environment: The Inflation Reduction Act (IRA) is expected to limit revenue from Medicare patients and reduce profits starting in 2026 due to inflation rebates and potential price negotiations.
Risks and Contingencies
- Patent Litigation: Corcept is appealing a December 2023 district court ruling that Teva's generic Korlym does not infringe Corcept's patents. Teva launched its generic in January 2024. Corcept also faces antitrust litigation from Teva and a separate lawsuit from insurance providers (Aetna, etc.) alleging unfair business practices.
- Government Investigation: The U.S. Attorney's Office for the District of New Jersey is investigating Corcept's sale and promotion of Korlym, relationships with healthcare professionals, and reimbursement practices. Corcept is not currently a defendant but is cooperating.
- Shareholder Derivative Actions: Multiple shareholder derivative lawsuits are pending, alleging breach of fiduciary duty and waste of corporate assets.
- Political/Legal Uncertainty: Risks related to the status of mifepristone (the active ingredient in Korlym) due to political debates on abortion, though the Supreme Court recently ruled against restricting access on procedural grounds.
Investor Verification Checklist
- Relacorilant NDA Status: Verify the FDA's review timeline and any potential requests for additional data prior to the December 30, 2025 target action date.
- Generic Competition Impact: Monitor the market share erosion of branded Korlym due to Teva's generic and the potential entry of Sun and Hikma generics.
- Patent Litigation Outcome: Track the appeal of the non-infringement ruling against Teva, as a loss could accelerate revenue decline.
- Government Investigation: Watch for updates on the New Jersey USAO investigation regarding sales practices and potential fines or settlements.
- SG&A Efficiency: Assess whether the significant increase in SG&A expenses (up 61% YoY) translates into sustainable revenue growth or margin compression.
- Cash Burn vs. Runway: Confirm that the $570.8 million cash position remains sufficient to fund operations through the relacorilant approval and commercialization without dilutive financing.